Sen. Chuck Grassley recently proposed placing a cap on how much drugmakers can charge on treatments in the U.S., but could the proposal end up creating more bottlenecks in an already complex system?
The author of a recent article published on Caffeinated Thoughts writes the “well-intentioned” plan could “further complicate the very problem he is trying to resolve.”
“Drug prices are already artificially high in the United States because of price controls,” the article states.
To read the full article on Caffeinated Thoughts, click here.
